格列吡嗪 (CP 2872; K 4024) 是一种有效的、具有口服活性的磺脲类抗糖尿病药物，可用于 2 型糖尿病研究，但不能用于 1 型糖尿病研究。
| Cas No. | 29094-61-9 |
| 别名 | 格列吡嗪; CP 28720; K 4024 |
| 化学名 | N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide |
| Canonical SMILES | CC1=NC=C(N=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3 |
| 分子式 | C21H27N5O4S |
| 分子量 | 445.54 |
| 溶解度 | ≥ 16.8mg/mL in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Glipizide(K 4024; CP 2872) is used to treat high blood sugar levels caused by a type of diabetes mellitus called type 2 diabetes.Target: Potassium ChannelGlipizide is an oral rapid- and short-acting anti-diabetic drug from the sulfonylurea class. It is classified as a second generation sulfonylurea, which means that it undergoes enterohepatic circulation. Mechanism of action is produced by blocking potassium channels in the beta cells of the islets of Langerhans. By partially blocking the potassium channels, the cell remains depolarized, increasing the time the cell spends in the calcium release stage, which results in signaling leading to calcium influx. The increase in calcium will initiate more insulin release from each beta cell. Sulfonylureas may also cause the decrease of serum glucagon and potentiate the action of insulin at the extrapancreatic tissues [1, 2]. References:
[1]. Chowdary, K.P. and Y.S. Rao, Design and in vitro and in vivo evaluation of mucoadhesive microcapsules of glipizide for oral controlled release: a technical note. AAPS PharmSciTech, 2003. 4(3): p. E39.
[2]. Rao, N.G., et al., Suicide by combined insulin and glipizide overdose in a non-insulin dependent diabetes mellitus physician: a case report. Med Sci Law, 2006. 46(3): p. 263-9. |
